In May 2007 Tabuk pharmaceutical launched “FACTIVE” in Saudi Arabia and soon will be launched in the rest of the Gulf region. Factive is an under licensed product from LG Korea, the product is a new generation respiratory Quinolone that possesses the optimal properties of ideal respiratory antibiotics. FACTIVE has a new mechanism of action due to its high affinity, dual targeting bacterial enzymes with low potentiality for resistance development compared with all other Quinolone.
As per FDA approval FACTIVE is the first antibiotic to treat Multi Drug Resistant Streptococcus Pneumonia, it also has the shortest treatment duration for Acute Exacerbation of Chronic Bronchitis and Community Acquired Pneumonia in 5 days. Tabuk is highly enthusiastic about the product which is showing marvelous results starting from the early launch.